Article

FDA approves new drug application for ophthalmic gel 3.5%

Akorn Inc. has announced approval of an FDA new drug application for ophthalmic gel 3.5%, a topical, ocular anesthetic formulation.

Lake Forest, IL-Akorn Inc. has announced approval of an FDA new drug application (NDA) for ophthalmic gel 3.5% (Akten), a topical, ocular anesthetic formulation. The gel is the first NDA ocular anesthetic approved by the FDA in 40 years, and it will be commercially available this October, according to a prepared statement issued by Akorn.

The novel, unit dose is a preservative-free lidocaine gel that is intended to be used in any ocular procedure that requires a topical anesthetic agent.

"This is a very important milestone in our company's history, because it represents our first internally developed NDA drug product," said Arthur S. Przybyl, Akorn's president and chief executive officer. "We expect [the ophthalmic gel] to become the standard of care whenever an ocular anesthetic is prescribed. [It] will be manufactured at our Somerset, NJ, facility, and [it] will be marketed directly to hospitals and ophthalmologists, with a targeted detail sales effort by our 65 sales representatives."

The estimated market size for the ophthalmic gel is approximately 11 million procedures annually, according to the company. The major procedures include cataract and refractive surgeries, LASIK, and intravitreal injection. The company said that is has filed two United States patents and one international patent on the formulation and method use of the ophthalmic gel.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
© 2025 MJH Life Sciences

All rights reserved.